1 / 22

Statistical Comparison of Immunogenicity Cutpoint Factors Using Log Transformation

Statistical Comparison of Immunogenicity Cutpoint Factors Using Log Transformation. Dingzhou (Dean) Li PharmaTx Statistics, Pfizer Global R&D MBSW, 2010. Definitions. Immunogenicity: Causing or capable of producing an immune response. Unwanted for target-binding drugs

gates
Télécharger la présentation

Statistical Comparison of Immunogenicity Cutpoint Factors Using Log Transformation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Statistical Comparison of Immunogenicity Cutpoint Factors Using Log Transformation Dingzhou (Dean) Li PharmaTx Statistics, Pfizer Global R&D MBSW, 2010

  2. Definitions • Immunogenicity: • Causing or capable of producing an immune response. • Unwanted for target-binding drugs • Desired for vaccines • Assay required for FIH • Anti-drug antibody (ADA) : • Binds to a portion of the drug thus preventing the drug from binding to its target • Affects the conformation of the drug so that when it binds to its target it is not functional. • Cross reactivity with endogenous proteins; greatest regulatory concern

  3. Immunoassays Bridging ELISA Bridging ECL Sandwich (non- bridging ELISA) SA-HRP Biotin- labeled drug Detection Antibody/reagent:HRP ADA ADA ADA Biotin Drug Drug Drug Fab

  4. From Quantitative to Qualitative • Quantitative • Continuous units of reference standard • Qualitative • Reference standard is not available • Ordinal or nominal • Quasi-quantitative • Continuous units of signals

  5. Endpoint Titer: A quasi-quantitative method • A way of expressing [Ab] in blood or serum • Related to the number of times you can dilute a sample of serum and still detect Ab • Titer = Reciprocal of the last dilution of a titration giving a measurable effect. • Reported log2 of the titer.

  6. Endpoint Titer Example RLU Titer=1894222 cutpoint

  7. Cutpoint • Cutpoint: Positive vs. Negative • How to calculate cutpoint? • Pooled negative controls (PNC) • Cutpoint = Mean(PNC) + cα*SD(PNC) • cα : Critical value at significance level α, depending on underlying distribution (e.g. c0.05 = 1.645 for normal distribution) • Parametric or nonparametric • Screening vs. Confirmatory

  8. Cutpoint Factor • For each plate in production, want to readily get the plate-specific cutpoint • Multiply the mean PNC by a factor • Cutpoint = Mean(PNC) * CPF • Need two steps…

  9. Two Steps • Step 1: Cutpoint factor determination • Negative control only • Step 2 : Production • Negative control, positive control, patient samples on the same plate • Endpoint titer, inference, sensitivity, etc

  10. Step 1: Cutpoint Factor Determination • 150 samples distributed on 6 plates • Sample: a serum sample from a subject • For each plate, • CPF (Plate) = Cutpoint (Plate)/Mean(Plate) • Average CPF for all the plates to get an overall CPF • This is the CPF for Step 2

  11. Step 1: Pooled Negative Controls cutpoint RLU

  12. Determination of CPF from PNC

  13. Step 2: Typical Production Plate Layout • Cutpoint = Mean(NC) * Overall CPF (from Step 1) • Use the cutpoint for endpoint titer calculation

  14. Comparing Cutpoint Factors • Are CPFs the same at different setups? • Reagent lot, serum type, etc • Important for process improvement • Decision making • How to compare CPF with repeated measures? • A subject may contribute multiple samples

  15. Statistical Treatment of CPF • Note for a certain plate, CPF = (Mean+ cα*SD)/Mean = 1+ cα*CV • CV has a noncentral t-distribution (Johnson and Welch, 1967) • Computationally difficult (though tools do exist) • Hard to extend to repeated measure scenarios • Alternative: Log-transform • In many cases, the signals (relative light units) are approximately log-normal

  16. Example: 25 Samples • Goodness of fit • Normal: p = 0.02 (S-W test) • LogNormal: p = 0.10 (Kolmogorov’s D)

  17. Log-transform Approach • It is well known that if X ~ then CV(X) = • When σ is small, • So statistical inference can be based upon variability of the logged data

  18. Example: 25 Samples • Noncentral t-distribution • CV = (0.088, 0.157) • CPF= (1.145, 1.258) • Log-transform • CV = (0.084, 0.150) • CPF = (1.138, 1.247)

  19. Homogeneity of Variability • Levene’s test • Fit 1st ANOVA to get residual variability estimate • Fit 2nd ANOVA on abs(residual) to test equal variance • Readily extends to repeated-measure cases • Models: • i: Lot; j: replicate; k: subject • 1st ANOVA: RLUijk = μ + replicatekj(i) +subjectk+ εijk => Get residualsrijk • 2nd ANOVA • Within-lot: rijk = μ + replicatej(i) +εijk • Between-lot: rijk = μ + loti +εijk

  20. Example • Two different reagent lots • Three plates at each lot • Samples from 30 subjects • Results: • In Lot 1, Plate a2 has higher variability than other plates • No significant difference in variability between Lots 1 and 2

  21. Discussions • Cutpoint analysis is crucial in various applications of the endpoint titer method • Cutpoint in most cases depends on the plate, experimental parameters, etc. So using a fixed cutpoint is not recommended • Uncertainty in CPF will translate to error in the endpoint titer

  22. Acknowledgements • Daniel Baltrukonis – Immunotox CoE • Jessica Duffy – Immunotox CoE • David Potter – PharmaTx Statistics

More Related